renal portfolio
Novartis Acquires Chinook Therapeutics for USD 3.5 Billion to Boost its Renal Portfolio
SG Tylor
Novartis, a global pharmaceutical giant, has finalized its deal to buy Chinook Therapeutics, a biotech company that specializes in developing ...
Novartis has agreed to purchase Chinook Therapeutics for USD 3.2 billion upfront (USD 40 per share), strengthening its new medicines strategy and renal portfolio in the process
SG Tylor
On 12 June 2023 Novartis revealed that it has reached a deal to purchase Chinook Therapeutics, a clinical-stage biopharmaceutical business ...
